Prepare AREXVY by reconstituting the lyophilized antigen component (a sterile white powder) with the accompanying adjuvant suspension component (an opalescent, colorless to pale brownish sterile...
AREXVY | FDA - U.S. Food and Drug Administration
Jun 2, 2023 · Package Insert - AREXVY; Demographic Subgroup Information – Respiratory Syncytial Virus Vaccine, Adjuvanted (AREXVY)
Administration | AREXVY (Respiratory Syncytial Virus Vaccine ...
AREXVY is supplied in 2 vials, an adjuvant suspension component (liquid) and a lyophilized antigen component (powder), that must be combined prior to administration. Use only the supplied adjuvant suspension component for reconstitution.
AREXVY is available in a 1-pack (1 single-dose vial of powder and 1 single-dose vial of suspension) and a 10-pack (10 single-dose vials of powder and 10 single-dose vials of suspension). Each 1-pack (box) contains:
Arexvy (RSV Vaccine): Usage, Side Effects, Warnings - Drugs.com
Jun 17, 2024 · Arexvy Package Insert. Review the Arexvy Prescribing Information for more detailed information about this medicine. Discuss any medical questions you have with your doctor or other health care provider.
Arexvy is indicated for active immunisation for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus in: • adults 60 years of age and older; • adults 50 through 59 years of age who are at increased risk for RSV disease. The use of this vaccine should be in accordance with official recommendations.
How does AREXVY work? AREXVY helps the body make antibodies and white blood cells to significantly reduce the chance of getting a RSV lower lung infection caused by RSV-A or RSV-B subtypes in adults aged 60 years and older. As AREXVY does not contain the RSV virus, it cannot cause an infection.